GlassScriptPhysician profile
Jonathan G Black
NPI 1659588382
$9,323.43
in general payments reported to CMS, 2019-2025
40 companies · $2,744 in 2025
The $2,744 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $454 · 2021: $892 · 2022: $1,638 · 2023: $1,259 · 2024: $1,878 · 2025: $2,744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,554 · Education: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,554.12 |
| Education | $327.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,579.33 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $974.85 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Octapharma USA, INC. | $761.35 | 2021-2024 | Cutaquig, Panzyga |
| Csl Behring | $751.53 | 2021-2025 | Haegarda, Andembry |
| Glaxosmithkline, LLC. | $710.74 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Biocryst US Sales Co., LLC | $611.01 | 2021-2025 | Orladeyo |
| Regeneron Healthcare Solutions, INC. | $548.18 | 2019-2025 | Dupixent |
| Optinose US, INC. | $427.35 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $334.54 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $324.84 | 2020-2025 | Cuvitru, Takhzyro |
| Genentech USA, INC. | $322.59 | 2019-2025 | Xolair |
| Grifols USA, LLC | $216.73 | 2019-2025 | Xembify |
| Pfizer INC. | $215.78 | 2019-2024 | |
| Abbvie INC. | $185.48 | 2022-2023 | Rinvoq |
| Amgen INC. | $168.90 | 2021-2025 | Tezspire |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.